Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Background: The tumor microenvironment (TME) consists of heterogeneous cell populations, including malignant cells and nonmalignant cells that support tumor proliferation, invasion, and metastasis through extensive crosstalk. The intra-tumor immune landscape is a critical factor influencing patient survival and response to immunotherapy. Methods: Gene expression data were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. Immune cell infiltration was determined by single-sample gene set enrichment analysis (ssGSEA) depending on the integrated immune gene sets from published studies. Univariate analysis was used to determine the prognostic value of the infiltrated immune cells. LASSO regression was performed to screen for the most survival-relevant immune cells. An immune-cell characteristic score (ICCS) model was constructed by using multivariate Cox regression analysis. Results: The immune cell infiltration patterns across 32 cancer types were identified, and patients in the high immune cell infiltration cluster had worse overall survival (OS) but better progression-free interval (PFI) compared to the low immune cell infiltration cluster. However, immune cell infiltration showed inconsistent prognostic value depending on the cancer type. High immune cell infiltration indicated a worse prognosis in LGG, GBM, and UVM, and favorable prognosis in ACC, CESE, CHOL, HNSC, LIHC, LUAD, SARC, and SKCM. LUAD prognosis was significantly influenced by the infiltration of 13 immune cell types, with high infiltration of all but Th2 cells correlating with a favorable prognosis. An ICCS model based on 6 most survival-relevant immune-cell populations was generated that classified patients into low- and high-ICCS groups with good and poor prognosis respectively. The multivariate and stratified analysis further revealed that the ICCS was an independent prognostic factor for LUAD. Conclusions: The infiltration of immune cells in 32 cancer types was quantified and considerable heterogeneity was observed in the prognostic relevance of these cells in different cancer types. An ICCS model was constructed for LUAD with competent prognostic performance, which can further deepen our understanding of the tumor microenvironment of lung adenocarcinoma and can have implications for immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Regression shrinkage and selection via the lasso
Tibshirani, R. (1996) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1996.tb02080.x · Cited by 51,482 · cited 4×
“By using LASSO regression analysis, six-cell populations including B cells, immature DCs, eosinophils, mast cells, granzyme K expressing CD8+ T cells, and Th2 cells were selected (Figures 5A,B).”
MethodInfluentialGSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · cited 1×
“The tumor-infiltrating immune cells are a critical player in tumor progression and immunotherapeutic response (29).”
BackgroundCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“(25) were generated using single-cell sequencing and measured in the other studies (3, 23, 24, 26) by microarray profiling.”
MethodAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“The latter consists of various immune cells, mesenchymal-origin cells, and the extracellular matrix (ECM) (1, 2), which influence all stages of tumorigenesis by directly interacting with the tumor cells (3, 4).”
BackgroundSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422 · cited 3×
“(25) were generated using single-cell sequencing and measured in the other studies (3, 23, 24, 26) by microarray profiling.”
BackgroundMethodSystematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890 · cited 2×
“Single-sample Gene Set Enrichment Analysis (ssGSEA) is an extension of Gene Set Enrichment Analysis (GSEA), which calculates separate enrichment scores for each pairing of a sample and gene set (16).”
BackgroundMethodThe prognostic landscape of genes and infiltrating immune cells across human cancers
Gentles, A. J., Newman, A. M., Liu, C. L., Bratman, S. V., Feng, W., Kim, D., Nair, V. S., Xu, Y., Khuong, A., Hoang, C. D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3909 · Cited by 3,118
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Chan, T. A., Yarchoan, M., Jaffee, E., Swanton, C., Quezada, S. A., Stenzinger, A., & Peters, S. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy495 · Cited by 2,683
T cell exclusion, immune privilege, and the tumor microenvironment
Joyce, J. A., & Fearon, D. T. (2015) · Science · doi:10.1126/science.aaa6204 · Cited by 2,473 · cited 1×
“Studies have confirmed the positive impact of T cells in tumor progression (7), and their exclusion from the TME leads to immune privilege (36).”
BackgroundLandscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E., & Gfeller, D. (2017) · eLife · doi:10.7554/elife.26476 · Cited by 1,384 · cited 1×
“(25) were generated using single-cell sequencing and measured in the other studies (3, 23, 24, 26) by microarray profiling.”
MethodŞenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Van Allen, E. M., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E., Luna, A., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1092-z · Cited by 968 · cited 2×
“This study is consistent with previously reported results that high levels of Th2 cells are associated with poor prognosis of clear cell renal cell carcinoma (30).”
BackgroundResultOkayama, H., Kohno, T., Ishii, Y., Shimada, Y., Shiraishi, K., Iwakawa, R., Furuta, K., Tsuta, K., Shibata, T., Yamamoto, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1403 · Cited by 874 · cited 1×
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodEffector and regulatory B cells: modulators of CD4+ T cell immunity
Lund, F. E., & Randall, T. D. (2010) · Nature Reviews Immunology · doi:10.1038/nri2729 · Cited by 638
Angell, H., & Galon, J. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.03.004 · Cited by 574 · cited 1×
“The immunological component of the TME acts as a two-edged sword that can either suppress or promote tumor development (5).”
BackgroundAngelova, M., Charoentong, P., Hackl, H., Fischer, M. L., Snajder, R., Krogsdam, A. M., Waldner, M. J., Bindea, G., Mlecnik, B., Galon, J., et al. (2015) · Genome Biology · doi:10.1186/s13059-015-0620-6 · Cited by 522 · cited 2×
“(25) were generated using single-cell sequencing and measured in the other studies (3, 23, 24, 26) by microarray profiling.”
BackgroundMethodBremnes, R. M., Busund, L.-T., Kilvær, T. L., Andersen, S., Richardsen, E., Paulsen, E. E., Hald, S., Khanehkenari, M. R., Cooper, W. A., Kao, S. C., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.015 · Cited by 502 · cited 2×
“The previous study has shown that the tumor-infiltrating immune cells are correlated with the development and progression of LUAD (11).”
BackgroundDistinct Role of Antigen-Specific T Helper Type 1 (Th1) and Th2 Cells in Tumor Eradication in Vivo
Nishimura, T., Iwakabe, K., Sekimoto, M., Ohmi, Y., Yahata, T., Nakui, M., Sato, T., Habu, S., Tashiro, H., Sato, M., et al. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.617 · Cited by 468 · cited 1×
“Th2 cells have an immunoregulatory role in tumor growth and can induce tumor cell necrosis by secreting type 2 cytokines within the TME (39, 40).”
BackgroundQuantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 407 · cited 4×
“There are currently two commonly used computational methods, one is ssGSEA, and the other is the deconvolution method, such as CIBERSORT (31).”
MethodInfluentialGenomic alterations in lung adenocarcinoma
Devarakonda, S., Morgensztern, D., & Govindan, R. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00077-7 · Cited by 404 · cited 1×
“Lung adenocarcinoma (LUAD) is the most common histological subtype (10).”
BackgroundLesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378 · cited 1×
“Immunosuppressive cells, such as tumor-associated macrophages (TAMs) and MDSCs, have a significant bearing on the survival of LUAD patients (37, 38).”
BackgroundDer, S. D., Sykes, J., Pintilie, M., Zhu, C.-Q., Strumpf, D., Liu, N., Jurisica, I., Shepherd, F. A., & Tsao, M.-S. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000042 · Cited by 372 · cited 1×
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodBotling, J., Edlund, K., Lohr, M., Hellwig, B., Holmberg, L., Lambe, M., Berglund, A., Ekman, S., Bergqvist, M., Pontén, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1139 · Cited by 359 · cited 1×
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodTumor-Infiltrating Immune Cells Act as a Marker for Prognosis in Colorectal Cancer
Ye, L., Zhang, T., Kang, Z., Guo, G., Sun, Y., Lin, K., Huang, Q., Shi, X., Ni, Z., Ding, N., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02368 · Cited by 332 · cited 1×
“Due to the heterogeneity of TME, the survival rate of tumor patients at the same pathologic stage may be significantly different (46).”
BackgroundTumor infiltrating immune cells in gliomas and meningiomas
Domingues, P., González-Tablas, M., Otero, Á., Pascual, D., Miranda, D., Ruiz, L., Sousa, P., Ciudad, J., Gonçalves, J. M., Lopes, M. C., et al. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.019 · Cited by 302 · cited 1×
“Studies show the infiltration of multiple immune cells in the lung TME (4, 11), including that of T lymphocytes, B cells, dendritic cells (DCs), macrophages, and natural killer (NK) cells (12).”
BackgroundEstimation of immune cell content in tumour tissue using single-cell RNA-seq data
Schelker, M., Feau, S., Du, J., Ranu, N., Klipp, E., MacBeath, G., Schoeberl, B., & Raue, A. (2017) · Nature Communications · doi:10.1038/s41467-017-02289-3 · Cited by 285 · cited 1×
“Therefore, when analyzing RNA sequencing data, it must be converted into “microarray-like” data before it can be used for subsequent analysis (33).”
MethodYamauchi, M., Yamaguchi, R., Nakata, A., Kohno, T., Nagasaki, M., Shimamura, T., Imoto, S., Saito, A., Ueno, K., Hatanaka, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043923 · Cited by 199 · cited 1×
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodBaghdadi, M., Wada, H., Nakanishi, S., Abe, H., Han, N., Putra, W. E., Endo, D., Watari, H., Sakuragi, N., Hida, Y., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1170 · Cited by 180 · cited 1×
“Immunosuppressive cells, such as tumor-associated macrophages (TAMs) and MDSCs, have a significant bearing on the survival of LUAD patients (37, 38).”
BackgroundTissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses
Oliver, A. J., Lau, P. K. H., Unsworth, A. S., Loi, S., Darcy, P. K., Kershaw, M. H., & Slaney, C. Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00070 · Cited by 169
Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment
Varn, F. S., Wang, Y., Mullins, D. W., Fiering, S., & Cheng, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2490 · Cited by 153 · cited 1×
“Non-small-cell lung cancer (NSCLC) and melanoma are two cancer types that respond to immunotherapy largely due to the high mutation burden of these tumors (43), which have been proposed to associate with tumor immune infiltration (44).”
BackgroundGanesan, A.-P., Johansson, M., Ruffell, B., Beltran, A., Lau, J., Jablons, D. M., & Coussens, L. M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301317 · Cited by 138 · cited 1×
“Therefore, it is not surprising that immunological parameters of LUAD, such as the infiltrating T cells, are important discriminants of tumor stratification, clinical outcomes, and patient survival (13, 14).”
BackgroundSerum IL-33 as a Diagnostic and Prognostic Marker in Non-small Cell Lung Cancer
Liang-an, H., Fu, Y., Zhang, D.-N., & Zhang, J. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.4.2563 · Cited by 106 · cited 1×
“Furthermore, the Th2 inflammatory cytokine IL-33 is associated with poor prognosis in lung cancer patients (41).”
BackgroundImmune cells in colorectal cancer: prognostic relevance and therapeutic strategies
Atreya, I., & Neurath, M. F. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.4.561 · Cited by 98
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy
Zemek, R. M., Chin, W. L., Nowak, A. K., Millward, M., Lake, R., & Lesterhuis, W. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00223 · Cited by 75 · cited 1×
“Among the 32 types of cancer, 9,112 individual tumor samples can be divided into two clusters: High CI and Low CI phenotypes, which can be interpreted as “hot” and “cold” tumors (34).”
BackgroundJabs, V., Edlund, K., König, H., Grinberg, M., Madjar, K., Rahnenführer, J., Ekman, S., Bergkvist, M., Holmberg, L., Ickstadt, K., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0187246 · Cited by 67 · cited 1×
“Microarray and clinical data of LUAD patients were obtained from the GSE31210 (n = 226) (17, 18), GSE37745 (n = 106) (19, 20), and GSE50081 (n = 128) (21) datasets of the GEO database.”
MethodThe paradoxical role of tumor-infiltrating immune cells in lung cancer
Zheng, X., Hu, Y., & Yao, C. (2017) · Intractable & Rare Diseases Research · doi:10.5582/irdr.2017.01059 · Cited by 67
Ohue, Y., Kurose, K., Nozawa, R., Isobe, M., Nishio, Y., Tanaka, T., Doki, Y., Hori, T., Fukuoka, J., Oka, M., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0266 · Cited by 57 · cited 1×
“Therefore, it is not surprising that immunological parameters of LUAD, such as the infiltrating T cells, are important discriminants of tumor stratification, clinical outcomes, and patient survival (13, 14).”
BackgroundHigh-throughput genomic profiling of tumor-infiltrating leukocytes
Newman, A. M., & Alizadeh, A. A. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.06.006 · Cited by 49 · cited 1×
“The recent advances in genomic sequencing and bioinformatics have enabled high throughput analysis and interpretation of complex disease-related datasets, which are ideal approaches to quantify the tumor-infiltrating immune cells of various cancers (15).”
Background
Cited by
Zheng, X., Wang, Y., & Qiu, X. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176840 · Cited by 10
Metadata
- Authors
- Zuo, S., Wei, M., Wang, S., Dong, J., & Wei, J.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2020-06-30
- Volume
- 11
- Pages
- 1218-1218
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W3039633408
- Cited by
- 224
- References
- 44
- FWCI
- 12.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.